Cargando…

Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction

BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brai...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilz, Georg, Sakic, Irma, Wipfler, Peter, Kraus, Jörg, Haschke-Becher, Elisabeth, Hitzl, Wolfgang, Trinka, Eugen, Harrer, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038591/
https://www.ncbi.nlm.nih.gov/pubmed/32089130
http://dx.doi.org/10.1186/s12987-020-0170-5
_version_ 1783500674091188224
author Pilz, Georg
Sakic, Irma
Wipfler, Peter
Kraus, Jörg
Haschke-Becher, Elisabeth
Hitzl, Wolfgang
Trinka, Eugen
Harrer, Andrea
author_facet Pilz, Georg
Sakic, Irma
Wipfler, Peter
Kraus, Jörg
Haschke-Becher, Elisabeth
Hitzl, Wolfgang
Trinka, Eugen
Harrer, Andrea
author_sort Pilz, Georg
collection PubMed
description BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brain barriers is a possible source. The aim was to clarify the relation between CXCL13 concentrations in CSF, CXCL13 concentrations in serum and blood–CSF barrier (BCSFB) function for a correct interpretation of the intrathecal origin of CXCL13. METHODS: We retrospectively analyzed CXCL13 of banked CSF/serum samples (n = 69) selected from patient records and categorized the CSF CXCL13 elevations as CXCL13 negative (< 30 pg/ml), low (30–100 pg/ml), medium (101–250 pg/ml), or high (> 250 pg/ml). CXCL13 concentrations in CSF and serum and the corresponding CSF/serum CXCL13 quotients (Qcxcl13) were compared to CSF/serum albumin quotients (QAlb) as a measure for BCSFB function. The CXCL13 negative category included two subgroups with normal and dysfunctional BCSFB. RESULTS: Serum CXCL13 concentrations were similar across categories with median levels around 100 pg/ml but differed between individuals (29 to > 505 pg/ml). Despite clear evidence in serum, CXCL13 was detectable only at trace amounts (medians 3.5 and 7.5 pg/ml) in CSF of the two CXCL13 negative subgroups irrespective of a normal or pathological QAlb. Moreover, we found no association between CSF and serum CXCL13 levels or between QAlb and CSF CXCL13 levels in any of the CSF CXCL13-delineated categories. CXCL13 apparently does not “leak” from blood into CSF. This implies an intrathecal origin also for low CSF CXCL13 levels and a caveat for analyzing the Qcxcl13, because higher serum than CSF concentrations arithmetically depress the Qcxcl13 resulting in misleadingly low CSF/serum quotients. CONCLUSION: We demonstrated that CXCL13 does not cross from blood into CSF, not even during severe BCSFB dysfunction. CSF CXCL13 elevations therefore most likely always are CNS-derived, which highlights their relevance as indicator of inflammatory CNS processes. We recommend data should not be corrected for BCSFB permeability (QAlb) and not to calculate CSF/serum quotients for CXCL13 as these may introduce error.
format Online
Article
Text
id pubmed-7038591
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70385912020-03-02 Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction Pilz, Georg Sakic, Irma Wipfler, Peter Kraus, Jörg Haschke-Becher, Elisabeth Hitzl, Wolfgang Trinka, Eugen Harrer, Andrea Fluids Barriers CNS Research BACKGROUND AND PURPOSE: Elevation of the chemokine CXCL13 in CSF frequently occurs during active and acute CNS inflammatory processes and presumably is associated with B cell-related immune activation. Elevation levels, however, vary a lot and “leaking” of CXCL13 from blood across dysfunctional brain barriers is a possible source. The aim was to clarify the relation between CXCL13 concentrations in CSF, CXCL13 concentrations in serum and blood–CSF barrier (BCSFB) function for a correct interpretation of the intrathecal origin of CXCL13. METHODS: We retrospectively analyzed CXCL13 of banked CSF/serum samples (n = 69) selected from patient records and categorized the CSF CXCL13 elevations as CXCL13 negative (< 30 pg/ml), low (30–100 pg/ml), medium (101–250 pg/ml), or high (> 250 pg/ml). CXCL13 concentrations in CSF and serum and the corresponding CSF/serum CXCL13 quotients (Qcxcl13) were compared to CSF/serum albumin quotients (QAlb) as a measure for BCSFB function. The CXCL13 negative category included two subgroups with normal and dysfunctional BCSFB. RESULTS: Serum CXCL13 concentrations were similar across categories with median levels around 100 pg/ml but differed between individuals (29 to > 505 pg/ml). Despite clear evidence in serum, CXCL13 was detectable only at trace amounts (medians 3.5 and 7.5 pg/ml) in CSF of the two CXCL13 negative subgroups irrespective of a normal or pathological QAlb. Moreover, we found no association between CSF and serum CXCL13 levels or between QAlb and CSF CXCL13 levels in any of the CSF CXCL13-delineated categories. CXCL13 apparently does not “leak” from blood into CSF. This implies an intrathecal origin also for low CSF CXCL13 levels and a caveat for analyzing the Qcxcl13, because higher serum than CSF concentrations arithmetically depress the Qcxcl13 resulting in misleadingly low CSF/serum quotients. CONCLUSION: We demonstrated that CXCL13 does not cross from blood into CSF, not even during severe BCSFB dysfunction. CSF CXCL13 elevations therefore most likely always are CNS-derived, which highlights their relevance as indicator of inflammatory CNS processes. We recommend data should not be corrected for BCSFB permeability (QAlb) and not to calculate CSF/serum quotients for CXCL13 as these may introduce error. BioMed Central 2020-02-24 /pmc/articles/PMC7038591/ /pubmed/32089130 http://dx.doi.org/10.1186/s12987-020-0170-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pilz, Georg
Sakic, Irma
Wipfler, Peter
Kraus, Jörg
Haschke-Becher, Elisabeth
Hitzl, Wolfgang
Trinka, Eugen
Harrer, Andrea
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title_full Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title_fullStr Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title_full_unstemmed Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title_short Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
title_sort chemokine cxcl13 in serum, csf and blood–csf barrier function: evidence of compartment restriction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038591/
https://www.ncbi.nlm.nih.gov/pubmed/32089130
http://dx.doi.org/10.1186/s12987-020-0170-5
work_keys_str_mv AT pilzgeorg chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT sakicirma chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT wipflerpeter chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT krausjorg chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT haschkebecherelisabeth chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT hitzlwolfgang chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT trinkaeugen chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction
AT harrerandrea chemokinecxcl13inserumcsfandbloodcsfbarrierfunctionevidenceofcompartmentrestriction